Physician profile
Ryan Donlon
NPI 1023609401
$5,525.42
in general payments reported to CMS, 2019-2025
20 companies · $1,505 in 2025
The $1,505 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.91 · 2023: $2,325 · 2024: $1,683 · 2025: $1,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,133.80 |
| Education | $379.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $895.46 | 2023-2025 | |
| Janssen Biotech, INC. | $742.64 | 2023-2025 | Tremfya |
| Abbvie INC. | $665.15 | 2023-2025 | |
| Ucb, INC. | $492.07 | 2023-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $484.05 | 2023-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $395.36 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $285.97 | 2023-2025 | Adbry |
| Lilly USA, LLC | $268.55 | 2023-2024 | Olumiant, Taltz |
| Amgen INC. | $246.44 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $205.23 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $168.13 | 2023 | Siliq, Jublia |
| Galderma Laboratories, L.P. | $166.04 | 2025 | Nemluvio |
| Incyte Corporation | $148.07 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $110.76 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $84.87 | 2023-2025 | Zoryve |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $62.38 | 2023 | |
| Organon LLC | $52.18 | 2025 | Vtama |
| Dermavant Sciences, INC. | $24.02 | 2023 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.14 | 2024 | Spevigo |
| Glaxosmithkline, LLC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Donlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.